Phase II study exploring reduction method of Lenvatinib for the patients with advanced hepatocellular carcinoma

Phase II study exploring reduction method of Lenvatinib for the patients with advanced hepatocellular carcinoma - Lenvatinib reduction study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032400

Enrollment

Registered

2018-04-26

Start date

2018-04-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Lenvatinib 8mg once daily for 14 days of each 3-week cycle Lenvatinib 4mg once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; receiving 8mg daily of Lenvatinib for 14 days or more; Child-Pugh score <=8; age >=20; ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: Refractory ascites or pleural effusion, history of hepatic encephalopathy, risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; allergy for Lenvatinib, or contrast agent of CT or/and MRI

Design outcomes

Primary

Measure	Time frame
Safety, Relative dose intensity	—

Countries

Japan

Contacts

Public ContactTakeshi Terashima

Kanazawa University Advanced Preventive Medical Sciences Research Center

tera@m-kanazawa.jp076-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026